公开(公告)号：EP2615183B1

公开(公告)日：2014-10-08

申请号：EP13163561.7

申请日：2009-05-13

申请人： Genomic Health, Inc. ,  Bristol-Myers Squibb Company

发明人： Baker, Joffre ,  Watson, Drew ,  Maddala, Tara ,  Shak, Steven ,  Mauro, David, J. ,  Ford, Shirin, K.

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

公开(公告)号：EP2615183A1

公开(公告)日：2013-07-17

申请号：EP13163561.7

申请日：2009-05-13

申请人： Genomic Health, Inc. ,  Bristol-Myers Squibb Company

发明人： Baker, Joffre ,  Watson, Drew ,  Maddala, Tara ,  Shak, Steven ,  Mauro, David, J. ,  Ford, Shirin, K.

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

摘要： The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.

摘要翻译： 本发明提供了有助于确定个体中EGFR表达的EGFR是否是EGFR抑制剂反应性癌症的方法和组合物，以及用于确定具有EGFR表达癌症的患者的可能性将表现出对 EGFR抑制剂治疗。 所述方法通常涉及确定与EGFR抑制剂反应性相关的基因产物的归一化表达水平。

公开(公告)号：EP2913405B1

公开(公告)日：2016-11-09

申请号：EP15152517.7

申请日：2011-07-25

申请人： Genomic Health, Inc.

发明人： Shak, Steve ,  Baehner, Frederick L. ,  Maddala, Tara ,  Lee, Mark ,  Pelham, Robert J. ,  Cowens, Wayne ,  Cherbavaz, Diana ,  Kiefer, Michael C. ,  Crager, Michael ,  Goddard, Audrey ,  Baker, Joffre

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G06F19/00

摘要： Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.

公开(公告)号：EP4083233A3

公开(公告)日：2023-01-25

申请号：EP22168567.0

申请日：2011-07-25

申请人： Genomic Health, Inc.

发明人： Shak, Steven ,  Baehner, Frederick ,  Maddala, Tara ,  Lee, Mark ,  Pelham, Robert ,  Cowens, Wayne ,  Cherbavaz, Diana ,  Kiefer, Michael ,  Crager, Michael ,  Goddard, Audrey ,  Baker, Joffre B.

IPC分类号： C12Q1/6886 ,  G01N33/574

摘要： Molecular assays that involve measurement of expression levels of prognostic biomarkers, or coexpressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.

公开(公告)号：EP4083233A2

公开(公告)日：2022-11-02

申请号：EP22168567.0

申请日：2011-07-25

申请人： Genomic Health, Inc.

发明人： Shak, Steven ,  Baehner, Frederick ,  Maddala, Tara ,  Lee, Mark ,  Pelham, Robert ,  Cowens, Wayne ,  Cherbavaz, Diana ,  Kiefer, Michael ,  Crager, Michael ,  Goddard, Audrey ,  Baker, Joffre B.

IPC分类号： C12Q1/6886 ,  G01N33/574

摘要： Molecular assays that involve measurement of expression levels of prognostic biomarkers, or coexpressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.

公开(公告)号：EP2913405A1

公开(公告)日：2015-09-02

申请号：EP15152517.7

申请日：2011-07-25

申请人： Genomic Health, Inc.

发明人： Shak, Steve ,  Baehner, Frederick L. ,  Maddala, Tara ,  Lee, Mark ,  Pelham, Robert J. ,  Cowens, Wayne ,  Cherbavaz, Diana ,  Kiefer, Michael C. ,  Crager, Michael ,  Goddard, Audrey ,  Baker, Joffre

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G06F19/00

摘要： Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.

摘要翻译： 分子检测确实涉及从前列腺癌患者获得的生物样品的生物标记物的预后，或共同过表达的生物标志物的表达水平的测量，并且所测量的表达水平的分析，以提供关于信息用于所述患者的可能的预后，和似然确实 所述患者将有前列腺癌的复发，或至肿瘤通过临床结果或融合TMPRSS2状态的似然性，在提供分类。